SQUAMOUS NSCLC EPIDEMIOLOGY

Lung Cancer Epidemiology
  • A specific histological type of NSCLC, squamous cell lung cancer (sqCLC) is an aggressive form of lung cancer representing approximately 25-30% of NSCLC cases1
  • The estimated median survival time of metastatic or advanced sqCLC is around 9-11 months1
  • In 2016, approximately 26.5% of all cancer deaths were due to bronchus and lung cancer2
  • In 2013, approximately 415,707 individuals lived with bronchus and lung cancer2
  • In 2018 the 5-year survival rate of patients with lung and bronchus cancer was approximately 18.7%2
  • In the United States, Lung Cancer is the leading cause of cancer deaths3
  • The estimated median survival time of patients with advanced or metastatic squamous NSCLC is 9-11 months4
  • Worldwide, lung cancer is the leading cause of cancer death in men3
  • Approximately 80-90% of lung cancer cases are attributed to cigarette use3
  • Approximately ≥80% of lung cancer cases are NSCLC3
  • An estimated 7-10% of patients with squamous NSCLC have EGFR overexpressing tumors4
  • An estimated 60% of patients with progressive lung cancer acquire resistance after initial response to first line treatments (afatinib, erlotinib, gefitinib)3

Resources and Additional Reading for NSCLC Epidemiology:

  1. Langer CJ, Obasaju C, Bunn P, et al. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Status and Future Impact of Treatment. Journal of Thoracic Oncology. 2016. Vol 11, No 12: 2066-2081
  2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Lung and Bronchus Cancer. https://seer.cancer.gov/statfacts/html/lungb.html
  3. Meza R, Meernik C, Jeon J, Cote ML. Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973-2010. PLoS ONE 10(3): e0121323. doi:10.1371/journal. pone.0121323
  4. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 5, 2017. Available at: https://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
  5. Langer CJ, Obasaju C, Bunn P, et al. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Status and Future Impact of Treatment. Journal of Thoracic Oncology. 2016. Vol 11, No 12: 2066-2081